biostudies-literatureArgiris ANCI NIH HHS3374-82https://www.ebi.ac.uk/biostudies/studies/S-EPMC3135694biostudies-literatureUnknown117(15)<h4>Background</h4>Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin.<h4>Methods</h4>Eligibility criteria included incurable ACC, any number of prior therapies but without an anthracycline, unidimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and ejection fraction within normal limits. Patients with stable disease for ≥9 months were excluded. Patients received bortezomib 1.3 mg/m(2) by intravenous (IV) push on Days 1, 4, 8, and 11, every 21 days until progression. Doxorubicin 20 mg/m(2) IV on Days 1 and 8 was added at the time of progression.<h4>Results</h4>Twenty-five patients were enrolled, of whom 24 wCancerA phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).PMC3135694CA39229U10 CA066636CA66636U10 CA013650U10 CA016116CA13650U10 CA039229U10 CA023318U10 CA021115CA16116U10 CA017145U10 CA027525CA27525CA17145CA21115U10 CA021115-25CA23318Forastiere AAArgiris ABurtness BDeconti RCAxelrod RSGhebremichael MfalseA phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).<h4>Background</h4>Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin.<h4>Methods</h4>Eligibility criteria included incurable ACC, any number of prior therapies but without an anthracycline, unidimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and ejection fraction within normal limits. Patients with stable disease for ≥9 months were excluded. Patients received bortezomib 1.3 mg/m(2) by intravenous (IV) push on Days 1, 4, 8, and 11, every 21 days until progression. Doxorubicin 20 mg/m(2) IV on Days 1 and 8 was added at the time of progression.<h4>Results</h4>Twenty-five patients were enrolled, of whom 24 w2011-01-01T00:00:00Z2011 Aug2025-04-22T20:32:21.341Z2019-03-27T03:07:02ZS-EPMC31356942124652510.1002/cncr.25852